Chapter 29
Use of Alcohol Septal Reduction Therapy to Facilitate Transcatheter Mitral Valve Replacement
Marvin H. Eng, Tiberio Frisoli, Dee Dee Wang, James C. Lee, Pedro A. Villablanca Spinetto,
Janet Wyman, William W. O'Neill,
Pedro A. Villablanca Spinetto
Henry Ford Hospital, Detroit, MI, USA
Search for more papers by this authorMarvin H. Eng, Tiberio Frisoli, Dee Dee Wang, James C. Lee, Pedro A. Villablanca Spinetto,
Janet Wyman, William W. O'Neill,
Pedro A. Villablanca Spinetto
Henry Ford Hospital, Detroit, MI, USA
Search for more papers by this authorBook Editor(s):Ron Waksman,
Toby Rogers,
Ron Waksman
Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA
Search for more papers by this authorToby Rogers
Cardiovascular Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA
Search for more papers by this authorFirst published: 12 March 2021
Summary
Transcatheter mitral valve implantation is a recently innovated procedure that began in the context of postsurgical repair or replacement degeneration requiring valve replacement. While treating mitral valve disease with transcatheter implantable prostheses, the complication of left ventricular outflow tract (LVOT) obstruction surprised operators and gave the interventional community pause about the generalizability of performing transcatheter mitral valve replacement (TMVR). LVOT obstruction historically occurred either in the natural history of hypertrophic obstructive cardiomyopathy (HOCM) or in postsurgical mitral valve repair. The process of alcohol septal ablation (ASA) begins with coronary angiography and then identifying candidate septal perforators that may supply blood to the myocardium of interest. Safety and effectiveness of the alcohol septal ablation for septal reduction therapy remains unquantified for non-HOCM patients.
References
- Cheung, A., Webb, J.G., Barbanti, M. et al. (2013). 5-year experience with transcatheter transapical mitral valve-in-valve implantation for bioprosthetic valve dysfunction. J. Am. Coll. Cardiol. 61: 1759–1766.
- Guerrero, M., Urena, M., Himbert, D. et al. (2018). 1-year outcomes of transcatheter mitral valve replacement in patients with severe mitral annular calcification. J. Am. Coll. Cardiol. 71: 1841–1853.
- Manabe, S., Kasegawa, H., Fukui, T. et al. (2012). Morphological analysis of systolic anterior motion after mitral valve repair. Interact. Cardiovasc. Thorac. Surg. 15: 235–239.
- Manabe, S., Kasegawa, H., Fukui, T. et al. (2013). Influence of left ventricular function on development of systolic anterior motion after mitral valve repair. J. Thorac. Cardiovasc. Surg. 146: 291–5.e1.
- Miura, T., Eishi, K., Yamachika, S. et al. (2011). Systolic anterior motion after mitral valve repair: predicting factors and management. Gen. Thorac. Cardiovasc. Surg. 59: 737–742.
- Loulmet, D.F., Yaffee, D.W., Ursomanno, P.A. et al. (2014). Systolic anterior motion of the mitral valve: a 30-year perspective. J. Thorac. Cardiovasc. Surg. 148: 2787–2793.
- Khalpey, Z., Shernan, S.K., Nascimben, L., and Aranki, S.F. (2013). Partial anterior leaflet valvuloplasty to avoid systolic anterior motion after mitral valve repair. Ann. Thorac. Surg. 95: 1462–1463.
- Lin, C.S., Chen, K.S., Lin, M.C. et al. (1991). The relationship between systolic anterior motion of the mitral valve and the left ventricular outflow tract Doppler in hypertrophic cardiomyopathy. Am. Heart J. 122: 1671–1682.
- Said, S.M., Schaff, H.V., Greason, K.L. et al. (2017). Reoperation for mitral paravalvular leak: a single-Centre experience with 200 patients†. Interact. Cardiovasc. Thorac. Surg. 25: 806–812.
- Walmsley, R. (1979). Anatomy of left ventricular outflow tract. Br. Heart J. 41: 263–267.
- Wang, D.D., Eng, M.H., Greenbaum, A.B. et al. (2017). Validating a prediction modeling tool for left ventricular outflow tract (LVOT) obstruction after transcatheter mitral valve replacement (TMVR). Catheter. Cardiovasc. Interv.
- Stone, G.W., Adams, D.H., Abraham, W.T. et al. (2015). Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part 2: endpoint definitions: a consensus document from the mitral valve academic research consortium. Eur. Heart J. 36: 1878–1891.
- Babaliaros, V.C., Greenbaum, A.B., Khan, J.M. et al. (2017). Intentional percutaneous laceration of the anterior mitral leaflet to prevent outflow obstruction during transcatheter mitral valve replacement: first-in-human experience. JACC Cardiovasc. Interv. 10: 798–809.
- Guerrero, M., Wang, D.D., Himbert, D. et al. (2017). Short-term results of alcohol septal ablation as a bail-out strategy to treat severe left ventricular outflow tract obstruction after transcatheter mitral valve replacement in patients with severe mitral annular calcification. Catheter. Cardiovasc. Interv. 90: 1220–1226.
- Sigwart, U. (1995). Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 346: 211–214.
- Veselka, J., Jensen, M.K., Liebregts, M. et al. (2016). Long-term clinical outcome after alcohol septal ablation for obstructive hypertrophic cardiomyopathy: results from the Euro-ASA registry. Eur. Heart J. 37: 1517–1523.
- Jensen, M.K., Prinz, C., Horstkotte, D. et al. (2013). Alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy: low incidence of sudden cardiac death and reduced risk profile. Heart 99: 1012–1017.
- Sorajja, P., Valeti, U., Nishimura, R.A. et al. (2008). Outcome of alcohol Septal ablation for obstructive hypertrophic cardiomyopathy. Circulation 118: 131–139.
- Sorajja, P., Ommen, S.R., Holmes, D.R. et al. (2012). Survival after alcohol Septal ablation for obstructive hypertrophic cardiomyopathy. Circulation 126: 2374–2380.
- Nagueh, S.F., Groves, B.M., Schwartz, L. et al. (2011). Alcohol septal ablation for the treatment of hypertrophic obstructive cardiomyopathy. A multicenter North American registry. J. Am. Coll. Cardiol. 58: 2322–2328.
- Noseworthy, P.A., Rosenberg, M.A., Fifer, M.A. et al. (2009). Ventricular arrhythmia following alcohol Septal ablation for obstructive hypertrophic cardiomyopathy. Am. J. Cardiol. 104: 128–132.
- ten Cate, F.J., Soliman, O.I.I., Michels, M. et al. (2010). Long-term outcome of alcohol septal ablation in patients with obstructive hypertrophic cardiomyopathy. Circ Heart Fail. 3: 362–369.
- Fernandes, V.L., Nielsen, C., Nagueh, S.F. et al. (2008). Follow-up of alcohol Septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: the Baylor and Medical University of South Carolina experience 1996 to 2007. J. Am. Coll. Cardiol. Intv. 1: 561–570.
- Maron, B.J., Gardin, J.M., Flack, J.M. et al. (1995). Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA study. Circulation 92: 785–789.
- Kim, L.K., Swaminathan, R.V., Looser, P. et al. (2016). Hospital volume outcomes after septal myectomy and alcohol septal ablation for treatment of obstructive hypertrophic cardiomyopathy: us nationwide inpatient database, 2003–2011. JAMA Cardiol. 1: 324–332.
- Valeti, U.S., Nishimura, R.A., Holmes, D.R. et al. (2007). Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive cardiomyopathy. J. Am. Coll. Cardiol. 49: 350–357.
